secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protagonist Therapeutics, Inc (PTGX)
CIK:        0001377121
Form:       8-K
Filed at:   2024-06-26T23:59:59+00:00
Accession:  0001104659-24-075162
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protagonist Therapeutics shareholders approve doubling of authorized common shares to 180M
--------------------------------------------------------------------------------

- Shareholders approved amendment to increase authorized common shares from 90M to 180M, effective June 21, 2024.
- Three Class II directors elected: Sarah O'Dowd, William Waddill, and Rusty Williams.
- Advisory vote on executive compensation approved: 33.9M for, 9.3M against.
- Ratification of Ernst & Young as independent auditor for FY2024 approved: 49.3M for, 115k against.
- All four proposals passed; no other matters submitted at annual meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1377121/000110465924075162/0001104659-24-075162-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1377121/000110465924075162/tm2418234d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-075162

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer